

ARTICLE

Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19

Marinella Lauriola^{1,†}, Arianna Pani^{2,†}, Giovanbattista Ippoliti³, Andrea Mortara⁴, Stefano Milighetti³, Marjeh Mazen³, Gianluca Perseghin^{3,5}, Daniele Pastori^{6,*}, Paolo Grosso^{7,‡} and Francesco Scaglione^{2,‡}

Conflicting evidence regarding the use of hydroxychloroquine (HCQ) and azithromycin for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection do exist. We performed a retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease 2019 (COVID-19). Of these, 297 were in combination treatment, 17 were on HCQ alone, and 63 did not receive either of these 2 drugs because of contraindications. The primary end point was in-hospital death. Mean age was 71.8 ± 13.4 years and 34.2% were women. We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment group, and 102 in HCQ + azithromycin treatment group (log rank test for Kaplan–Meier curve $P < 0.001$). At multivariable Cox proportional hazard regression analysis, age (hazard ratio (HR) 1.057, 95% confidence interval (CI) 1.035–1.079, $P < 0.001$), mechanical ventilation/continuous positive airway pressure (HR 2.726, 95% CI 1.823–4.074, $P < 0.001$), and C reactive protein above the median (HR 2.191, 95% CI 1.479–3.246, $P < 0.001$) were directly associated with death, whereas use of HCQ + azithromycin (vs. no treatment; HR 0.265, 95% CI 0.171–0.412, $P < 0.001$) was inversely associated. In this study, we found a reduced in-hospital mortality in patients treated with a combination of HCQ and azithromycin after adjustment for comorbidities. A large randomized trial is necessary to confirm these findings.

Study Highlights

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?

✓ Few clinical evidences are available regarding the use of hydroxychloroquine (HCQ) and azithromycin for patients with coronavirus disease 2019 (COVID-19), despite that this combination has been the most used worldwide so far.

WHAT QUESTION DID THIS STUDY ADDRESS?

✓ This study evaluates the relationship between combination therapy of HCQ and azithromycin and in-hospital mortality in patients with severe acute respiratory syndrome coronavirus 2 infection-related pneumonia.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?

✓ This study reveals an inverse relation between HCQ and azithromycin use and in-hospital mortality, when compared with HCQ alone or no treatment. The combination was safe as patients with contraindications were excluded.

HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?

✓ This efficacy analysis on a large sample that shows the potential efficacy of the combination of HCQ and azithromycin in COVID-19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is spreading worldwide since December 2019 and still no proven effective therapy has been found. First therapy proposed to treat coronavirus disease 2019 (COVID-19) has been the association of lopinavir-ritonavir, a protease inhibitor approved for HIV infection. However, Cao *et al.* observed no benefit comparing lopinavir-ritonavir treatment of hospitalized patients with severe COVID-19,¹ and this treatment is currently not

recommended. Currently, only remdesivir has been approved for COVID-19 treatment, as it reduced recovery time by 4 days in 1,063 patients randomized to either remdesivir 200 mg loading dose followed by 100 mg daily or placebo for up to 10 days² with a similar rate of adverse events between the 2 groups.³ However, no effect on in-hospital mortality was found.

Chloroquine and its derivative hydroxychloroquine (HCQ), based on few preclinical studies, have also been proposed

[†]These authors contributed equally to this work.

[‡]These authors should be considered joint senior authorship.

¹Infectious Disease Department, Policlinico di Monza, Monza, Italy; ²Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy; ³Internal Medicine Department, Policlinico di Monza, Monza, Italy; ⁴Cardiology Department, Policlinico di Monza, Monza, Italy; ⁵Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Milan, Italy; ⁶Department of Clinical, Internal, Anesthesiologic, and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy; ⁷Intensive Care Unit, Policlinico di Monza, Monza, Italy. *Correspondence: Daniele Pastori (daniele.pastori@uniroma1.it)

Received: June 23, 2020; accepted: July 13, 2020. doi:10.1111/cts.12860

as therapies for COVID-19. A Chinese randomized trial in patients with mild disease showed a significantly shorter recovery time in the group treated with HCQ vs. the standard of care along with a radiological improvement.⁴ Differently, a retrospective study performed in the United States Veterans Health Administration medical centers found an increased mortality associated with the treatment with HCQ.⁵ Moreover, an observational study has shown no significant association between HCQ use and risk of intubation or death.⁶ Furthermore, a recent randomized controlled trial has found no differences between patients treated with HCQ plus the standard of care vs. the standard of care alone in terms of virus elimination.⁷

On the basis of a very small nonrandomized study, azithromycin has been proposed as possible treatment in association with HCQ.⁸ Azithromycin, is an antibiotic belonging to the class of macrolides, with some proven efficacy in acute respiratory distress syndrome.^{9,10} It is known to have immunomodulatory properties through the polarization of macrophages toward the reparative state¹¹ and the reduction in the production of pro-inflammatory cytokines, such as IL-8, IL-6, TNF alpha,¹² and iNOS expression.¹³ Recently, two large retrospective studies evaluating in-hospital mortality associated with the use of the combination of HCQ and azithromycin (or another macrolide, such as clarithromycin), have shown no benefits.¹⁴

Despite the lack of a proven clinical efficacy and some concerns regarding the possible QT prolongations caused by the association of HCQ and azithromycin,¹⁵ given the low price and the wide availability, the association of these two drugs has become the most used treatment in patients with moderate-severe COVID-19.

Because of the urgent need to find answers to the many questions posed by the fight to SARS-CoV2 infection and some negative evidences regarding the use of HCQ, we here propose a retrospective observational study to assess the efficacy of the combination of HCQ plus azithromycin for hospitalized patients with medium-severe COVID-19.

METHODS

Study design and participants

We conducted this study at the Policlinico of Monza, a highly specialized hospital based in Lombardy, which have been designated as one of the centers dedicated to treat patients with COVID-19 during the emergency. We have enrolled all consecutive adult patients diagnosed with COVID-19 aged at least 18 years admitted to our hospital from February 27, 2020, to the April 20, 2020. The only exclusion criteria applied were the presence of contraindications to HCQ or azithromycin (see below).

Patients have been considered enrolled if they had positivity to SARS-CoV-2 real-time polymerase chain reaction testing of oropharyngeal or nasopharyngeal swab specimen (according to the World Health Organization (WHO) guidance); radiographic evidence of pulmonary infiltrates at computed tomography scan and clinical documentation of lower respiratory symptoms, or SpO₂ ≤ 94% on room air. Specimens from the upper respiratory tract, lower respiratory tract, or both and computed tomography scan were obtained on the first day of hospitalization. The results of

this clinical trial are reported in accordance with STROBE guidelines.

Data regarding demographic, clinical, pharmacological, biochemical (including C reactive protein (CRP) and white blood cells (WBCs)), microbiological information have been manually abstracted independently by three investigators from medical records M.L., S.M., and M.M. Every discordance has been discussed and adjudicated according to the majority.

Treatments

We have divided our cohort into three groups according to the COVID-19 treatment received: (i) no treatments, (ii) HCQ alone, and (iii) combination of HCQ and azithromycin. All treatments have been initiated the first day of hospitalization. According to institutional clinical guidelines all patients had been administered HCQ and azithromycin except those with a contraindication, such as history of G6PD deficiency, cirrhosis, long QT syndrome, or porphyria of any classification, echocardiogram with corrected QT interval ≥ 500 msec, and known hypersensitivity to HCQ or 4-aminoquinoline derivative or macrolides. Patients with contraindication received HCQ alone or no treatment according to clinical judgment. Hydroxychloroquine has been administered at the dose of 200 mg t.i.d. (alone or in combination) and azithromycin at the dose of 500 milligrams q.d. for 10 days. Patients have been closely monitored during treatment. Echocardiogram has been performed before and after the treatment and in case of electrolytic imbalances and treatment interruption was considered if corrected QT > 500 ms. Patients with cardiologic comorbidities and risk factors have been monitored with cardiac telemetry. Because hypokalemia and hypomagnesemia are associated with increased risk of serious arrhythmia, correction of hypokalemia to a level > 4 mEq/L and hypomagnesemia to a level of > 2 mg/dL was performed when necessary.¹⁶

Patients have been followed up throughout the hospitalization. The primary end point was death.

Statistical analysis

Categorical variables were reported as percentage and compared by the χ^2 test. Continuous variables were expressed as mean ± SD and Student *t*-test was used to compare means. The analysis of variance test was used to compare groups. A first descriptive analysis of the study cohort according to different treatments has been performed.

Survival Kaplan–Meier curves were run to investigate the primary end point of in-hospital death according to treatment groups and compared by the log rank test. Univariable and multivariable proportional hazard Cox regression analysis was used to estimate the relative hazard ratio (HR) with 95% confidence interval (95% CI) for each variable. All available variables were entered as covariates in the final model. For the Cox regression analysis, CRP and WBCs were dichotomized according to the median value. Only *P* values < 0.05 were considered statistically significant. All the tests used are two-sided and the analyses were performed using electronic software packages (SPSS-25.0, IBM SPSS, Armonk, NY, and MedCalc, MedCalc Software Ltd, Ostend, Belgium).

RESULTS

Table 1 reports patients' characteristics according to treatment groups. Patients treated with HCQ and azithromycin were younger than those treated with HCQ alone or untreated, and were more likely to be treated with continuous positive airway pressure (CPAP; **Table 1**).

Conversely these patients had a lower prevalence of cardiovascular and cerebrovascular disease (**Table 1**). A similar value of CRP and WBCs was present among groups.

Length of stay was higher in the combination therapy group (**Table 1**).

In-hospital mortality

We recorded 146 deaths: 35 in no treatment, 7 in HCQ treatment, and 102 in the HCQ + azithromycin treatment groups (log rank test $P < 0.001$; **Figure 1**).

Univariable Cox regression analysis showed that age, use of CPAP or mechanical ventilation, hypertension, prevalent cardiovascular and cerebrovascular disease, chronic

Table 1 Characteristics of patients according to treatments

	Treatment groups				P value*
	Overall (n = 377)	None (n = 63)	HCQ (n = 17)	HCQ + azithromycin (n = 297)	
Age	71.8 ± 13.4	75.4 ± 11.9	76.3 ± 13.1	70.8 ± 13.6	0.018
Women, %	34.2	33.3	52.9	33.3	0.250
CPAP, %	13.0	3.2	5.9	15.5	0.021
Mechanical ventilation, %	12.5	12.7	11.8	12.5	0.995
CPAP + mechanical ventilation, %	22.8	15.9	17.6	24.6	0.285
Hypertension, %	63.4	66.7	64.7	62.6	0.827
Diabetes, %	18.8	20.6	23.5	18.2	0.794
Cancer, %	14.1	14.3	23.5	13.5	0.509
Cardiovascular disease, %	34.2	47.6	23.5	32.0	0.038
COPD, %	13.0	20.6	17.6	11.1	0.105
Cerebrovascular disease, %	16.2	28.6	29.4	12.8	0.003
Autoimmune disease, %	7.4	7.9	11.8	7.1	0.762
Obesity, %	8.0	4.8	11.8	8.4	0.522
CRP ^a	106.1 ± 89.3	108.3 ± 87.4	92.1 ± 82.6	106.5 ± 90.3	0.796
WBCs	7,783.0 ± 3,801.2	8,181.0 ± 4,767.1	8,423.5 ± 4,216.9	7,662.0 ± 3,544.2	0.480
Length of stay, days	13.3 ± 9.7	7.1 ± 6.9	6.8 ± 4.6	14.9 ± 9.8	<0.001

COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; CRP, C reactive protein; HCQ, hydroxychloroquine; WBCs, white blood cells.

^aData missing in two patients.

*Among groups.




Figure 1 Kaplan Meier curves for in-hospital mortality according to different treatments. HCQ, hydroxychloroquine.




Figure 2 Forest plot of univariable hazard ratio of factors associated with in-hospital death. CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure.

Table 2 Multivariable Cox proportional hazard regression analysis of factors associated with in-hospital death

	HR	95.0% CI		P value
		Lower	Upper	
Female sex	0.715	0.482	1.059	0.094
Age	1.057	1.035	1.079	0.000
MV + CPAP	2.726	1.823	4.074	0.000
Hypertension	1.492	0.997	2.232	0.052
Diabetes	1.220	0.813	1.830	0.337
Cancer	1.186	0.736	1.912	0.483
Cardiovascular disease	1.249	0.869	1.795	0.229
COPD	1.322	0.828	2.110	0.243
Cerebrovascular disease	1.037	0.671	1.603	0.869
Autoimmune disease	0.851	0.410	1.765	0.664
Obesity	1.329	0.779	2.268	0.297
WBC above the median	1.074	0.761	1.516	0.684
CRP above the median	2.191	1.479	3.246	0.000
HCQ (vs. no treatment)	1.108	0.536	2.293	0.782
HCQ + azithromycin (vs. no treatment)	0.265	0.171	0.412	0.000

CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPAP, continuous positive airway pressure; CRP, C reactive protein; HCQ, hydroxychloroquine; HR, hazard ratio; MV, mechanical ventilation; WBCs, white blood cells.

obstructive pulmonary disease (COPD), CRP, and WBCs above the median were associated with death (**Figure 2**).

At multivariable Cox proportional hazard regression analysis (**Table 2**), age (HR 1.057, 95% CI 1.035–1.079, $P < 0.001$), mechanical ventilation/CPAP (HR 2.726, 95% CI 1.823–4.074, $P < 0.001$), CRP above the median (HR 2.191, 95% CI 1.479–3.246, $P < 0.001$) were directly associated with death, whereas use of HCQ + azithromycin (vs. no

treatment; HR 0.265, 95% CI 0.171–0.412, $P < 0.001$) was inversely associated.

No fatal arrhythmias have been observed during treatment.

DISCUSSION

The main result of our observational cohort study is that found a beneficial effect of combination therapy of HCQ + azithromycin on in-hospital mortality in patients with COVID-19. This result is in contrast with the study by Rosenberg *et al.* and reasons accounting for these differences may be several. First, our cohort is younger with a lower prevalence of diabetes; furthermore, in the study by Rosenberg *et al.*, it is not reported the proportion of patients treated with CPAP/mechanical ventilation, which may affect mortality rate. In our study, a similar value of CRP and WBCs was found among groups, which were therefore homogenous. Similarly to other studies,^{5–7} we did not find a reduction of mortality in patients administered HCQ alone.

The main problem of efficacy of HCQ against SARS-CoV2 is probably linked to drug dosing. HCQ has shown to have *in vitro* activity against SARS-CoV2, but half maximal effective concentration needed to explicate an antiviral activity is 20 times higher than concentrations used for malaria treatment.^{17–19} A physiologically-based pharmacokinetic (PBPK) model based on *in vitro* and *in vivo* pharmacokinetic (PK) data developed by Yao *et al.*¹⁹ suggested an effective dose of HCQ of 400 mg b.i.d. for the first 4 treatment days, followed by 200 mg b.i.d. for other 4 days. According to the PK evaluation performed by Perinel *et al.*²⁰ in critical patients, a dose of 800 mg q.d. should be more appropriate to rapidly achieve therapeutic concentrations. In studies reporting nonefficacy of HCQ, doses used to treat patients have not being declared.^{5,6} However, it should be pointed out that HCQ PBPK models and simulations to predict lung

HCQ concentrations, have been based exclusive on rat pre-clinical *in vivo* studies. Furthermore, the PK data have been obtained only with healthy population. Thus, the predictive value of proposed models should be improved with more specific data reflecting HCQ disposition in tissues, plasma, and immunity cells.²¹ Anyway, despite its limitations, PBPK modeling is one of the most valuable approaches to estimate tissue-specific drug concentrations.²²

Because of the risk of arrhythmias, the dosage used in many patients was the one approved in malaria and autoimmune diseases. Similarly, in our study, HCQ has been administered with the schedule dose 200 mg t.i.d. With high probability this dose is insufficient to reach an appropriate therapeutic concentration.

Conversely, the combination therapy with azithromycin significantly increases efficacy. This effect may be due to both the early start of treatment and the relative high dose of azithromycin used, but also to the synergy between azithromycin and HCQ due to the different binding sites. Azithromycin interacts with the ganglioside-binding domain of SARS-CoV-2 spike protein, whereas HCQ molecules can saturate virus attachment sites on gangliosides in the vicinity of the primary coronavirus receptor ACE-2.²³ According to this model, azithromycin is directed against the virus, whereas HCQ is directed against cellular adhesion cofactors. Binding to these two sites can lead to a synergistic antiviral mechanism at the plasmatic membrane level.²³ Furthermore, azithromycin may be responsible for less bacterial complications in these patients, leading to a less severe disease.

In fact, in contrast with other studies,^{24–27} we have recorded fewer drug-related adverse effects. This is due both to the exclusion of patients with risk factors and to a strict monitoring protocol of adverse effect, included careful prevention of electrolytes imbalances. This is an important point in the management of patients with COVID-19, because the severity of this disease is inherently associated with lower serum concentrations of sodium, potassium, and calcium.²⁸ Despite this apparent safety profile in a strictly monitored cohort in which we excluded patients with contraindications and corrected electrolytes imbalance during in-hospital staying, we cannot exclude that these drugs may have side effects in some high-risk subgroups of patients, such as those with preexisting cardiovascular disease, or those taking drugs already causing a QT interval prolongation. In these cases, the risk-benefit ratio of using these drugs should be carefully considered.

As far as no effective drugs to reduce mortality in patients with COVID-19 has been found, our findings show a beneficial effect of this combination therapy may have clinical implications for the management of these patients. It is also noteworthy that azithromycin and HCQ are inexpensive drugs that might be easily available to use on large samples of populations with a potential benefit also in low-income countries.

There are also several limitations to acknowledge. A first limitation relates to the study design, as we performed a single-center observational study, which does not allow to completely correct for confounders. Only a randomized double-blind clinical trial would provide more solid evidence. However, similar characteristics of patients among groups

were found along with a similar inflammation degree as shown by WBC and CRP. Furthermore, we included white patients, thus the generalizability of our findings to other populations is uncertain. Finally, despite in-hospital death is a strong end point, it may be sometimes challenging to identify the exact cause of death in these patients.

In conclusion, this study found a lower mortality rate in patients with COVID-19 treated with a combination of HCQ and azithromycin. Reasons for this association need to be further investigated.

Funding. No funding was received for this work.

Conflict of Interest. All authors declared no competing interests for this work.

Author Contributions. M.L., A.P., G.I., A.M., S.M., M.M., G.P., D.P., P.G., and F.S. wrote the manuscript. A.P., F.S., and M.L. designed the research. D.P. analyzed the data.

1. Cao, B. *et al.* A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. *N. Engl. J. Med.* **382**, 1787–1799 (2020).
2. Beigel, J.H. *et al.* Remdesivir for the treatment of Covid-19 - preliminary report. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2007764>.
3. Humeniuk, R. *et al.* Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID-19, in healthy subjects. *Clin. Transl. Sci.* <https://doi.org/10.1111/cts.12840>.
4. Zhaowei Chen, J.H. *et al.* Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv.* <https://doi.org/10.1101/2020.03.22.20040758>.
5. Magagnoli, J. *et al.* Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv.* <https://doi.org/10.1101/2020.04.16.20065920>.
6. Geleris, J. *et al.* Observational study of hydroxychloroquine in hospitalized patients with Covid-19. *N. Engl. J. Med.* **382**, 2411–2418 (2020).
7. Tang, W. *et al.* Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* **369**, m1849 (2020).
8. Gautret, P. *et al.* Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int. J. Antimicrob. Agents.* <https://doi.org/10.1016/j.ijantimicag.2020.105949>.
9. Kawamura, K. *et al.* Efficacy of azithromycin in sepsis-associated acute respiratory distress syndrome: a retrospective study and propensity score analysis. *Springerplus* **5**, 1193 (2016).
10. Kawamura, K., Ichikado, K., Takaki, M., Eguchi, Y., Anan, K. & Suga, M. Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center. *Int. J. Antimicrob. Agents* **51**, 918–924 (2018).
11. Cory, T.J. *et al.* Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. *J. Cyst. Fibros.* **13**, 164–171 (2014).
12. Zimmermann, P., Ziesenitz, V.C., Curtis, N. & Ritz, N. The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. *Front. Immunol.* **9**, 302 (2018).
13. Gao, X., Ray, R., Xiao, Y. & Ray, P. Suppression of inducible nitric oxide synthase expression and nitric oxide production by macrolide antibiotics in sulfur mustard-exposed airway epithelial cells. *Basic Clin. Pharmacol. Toxicol.* **103**, 255–261 (2008).
14. Rosenberg, E.S. *et al.* Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. *JAMA* **323**, 2493 (2020).
15. Pani A., Marinella, L., Romandini, A. & Scaglione, F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. *Int. J. Antimicrob. Agents.* <https://doi.org/10.1016/j.ijantimicag.2020.106053>.
16. Naksuk, N., Lazar, S. & Peeraphatit, T.B. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. *Eur. Heart J. Acute Cardiovasc. Care* **9**, 215–221 (2020).
17. Al-Kofahi, M. *et al.* Finding the dose for hydroxychloroquine prophylaxis for COVID-19: the desperate search for effectiveness. *Clin. Pharmacol. Ther.* <https://doi.org/10.1002/cpt.1874>.
18. Liu, J. *et al.* Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov.* **6**, 16 (2020).

19. Yao, X. *et al.* In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2). *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciaa237>.
20. Perinel, S. *et al.* Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients. *Clin. Infect. Dis.* <https://doi.org/10.1093/cid/ciaa394>.
21. Arnold, S.L.M. & Buckner, F. Hydroxychloroquine for treatment of SARS-CoV-2 infection? Improving our confidence in a model-based approach to dose selection. *Clin. Transl. Sci.* **13**, 642–645 (2020).
22. Rowland Yeo, K. *et al.* Impact of disease on plasma and lung exposure of chloroquine, hydroxy-chloroquine and azithromycin: application of PBPK modelling. *Clin. Pharmacol. Ther.* <https://doi.org/10.1002/cpt.1955>.
23. Fantini, J., Chahinian, H. & Yahi, N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. *Int. J. Antimicrob. Agents.* <https://doi.org/10.1016/j.ijantimicag.2020.10602>.
24. Bonow, R.O., Hernandez, A.F. & Turakhia, M. Hydroxychloroquine, coronavirus disease 2019, and QT prolongation. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1782>.
25. Mercurio, N.J. *et al.* Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1834>.
26. Bessiere, F. *et al.* Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit. *JAMA Cardiol.* <https://doi.org/10.1001/jamacardio.2020.1787>.
27. Chang, D. *et al.* Inpatient use of ambulatory telemetry monitors for COVID-19 patients treated with hydroxychloroquine and/or azithromycin. *J. Am. Coll. Cardiol.* **75**, 2992–2993 (2020).
28. Lippi, G., South, A.M. & Henry, B.M. Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19). *Ann. Clin. Biochem.* **57**, 262–265 (2020).

© 2020 The Authors. *Clinical and Translational Science* published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.